The Experts below are selected from a list of 207 Experts worldwide ranked by ideXlab platform
Andrea Carmine Belin - One of the best experts on this subject based on the ideXlab platform.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort
The Journal of Headache and Pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:Background We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417 , an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881 , in MME (Membrane Metalloendopeptidase). Results We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. Conclusion In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort.
The journal of headache and pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417, an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881, in MME (Membrane Metalloendopeptidase). We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.
Caroline Ran - One of the best experts on this subject based on the ideXlab platform.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort
The Journal of Headache and Pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:Background We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417 , an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881 , in MME (Membrane Metalloendopeptidase). Results We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. Conclusion In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort.
The journal of headache and pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417, an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881, in MME (Membrane Metalloendopeptidase). We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.
Alexander Yu Nikitin - One of the best experts on this subject based on the ideXlab platform.
-
Membrane Metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin-releasing peptide on stem/progenitor cells
Oncogenesis, 2020Co-Authors: Chiehyang Cheng, Zongxiang Zhou, Meredith Stone, David M Nanus, Andrea Flesken-nikitin, Alexander Yu NikitinAbstract:Aberrant neuroendocrine signaling is frequent yet poorly understood feature of prostate cancers. Membrane Metalloendopeptidase (MME) is responsible for the catalytic inactivation of neuropeptide substrates, and is downregulated in nearly 50% of prostate cancers. However its role in prostate carcinogenesis, including formation of castration-resistant prostate carcinomas, remains uncertain. Here we report that MME cooperates with PTEN in suppression of carcinogenesis by controlling activities of prostate stem/progenitor cells. Lack of MME and PTEN results in development of adenocarcinomas characterized by propensity for vascular invasion and formation of proliferative neuroendocrine clusters after castration. Effects of MME on prostate stem/progenitor cells depend on its catalytic activity and can be recapitulated by addition of the MME substrate, gastrin-releasing peptide (GRP). Knockdown or inhibition of GRP receptor (GRPR) abrogate effects of MME deficiency and delay growth of human prostate cancer xenografts by reducing the number of cancer-propagating cells. In sum, our study provides a definitive proof of tumor-suppressive role of MME, links GRP/GRPR signaling to the control of prostate stem/progenitor cells, and shows how dysregulation of such signaling may promote formation of castration-resistant prostate carcinomas. It also identifies GRPR as a valuable target for therapies aimed at eradication of cancer-propagating cells in prostate cancers with MME downregulation.
-
Membrane Metalloendopeptidase suppresses prostate carcinogenesis by attenuating effects of gastrin releasing peptide on stem progenitor cells
bioRxiv, 2019Co-Authors: Chiehyang Cheng, Zongxiang Zhou, Meredith Stone, Bao Lu, Andrea Fleskennikitin, David M Nanus, Alexander Yu NikitinAbstract:Aberrant neuroendocrine signaling is frequent yet poorly understood feature of prostate cancers. Membrane Metalloendopeptidase (MME) is responsible for the catalytic inactivation of neuropeptide substrates, and is downregulated in nearly 50% of prostate cancers. However its role in prostate carcinogenesis, including formation of castration-resistant prostate carcinomas, remains uncertain. Here we report that MME cooperates with PTEN in suppression of carcinogenesis by controlling activities of prostate stem/progenitor cells. Lack of MME and PTEN results in development of adenocarcinomas characterized by propensity for vascular invasion and formation of proliferative neuroendocrine clusters after castration. Effects of MME on prostate stem/progenitor cells depend on its catalytic activity and can be recapitulated by addition of the MME substrate, gastrin-releasing peptide (GRP). Knockdown or inhibition of GRP receptor (GRPR) abrogate effects of MME deficiency, and delay growth of human prostate cancer xenografts by reducing the number of cancer propagating cells. In sum, our study provides a definitive proof of tumor suppressive role of MME, links GRP/GRPR signaling to the control of prostate stem/progenitor cells, and shows how dysregulation of such signaling may promote formation of castration-resistant prostate carcinomas. It also identifies GRPR as a valuable target for therapies aimed at eradication of cancer propagating cells in prostate cancers with MME downregulation.
Carmen Fourier - One of the best experts on this subject based on the ideXlab platform.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort
The Journal of Headache and Pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:Background We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417 , an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881 , in MME (Membrane Metalloendopeptidase). Results We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. Conclusion In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort.
The journal of headache and pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417, an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881, in MME (Membrane Metalloendopeptidase). We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.
Elisabet Waldenlind - One of the best experts on this subject based on the ideXlab platform.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort
The Journal of Headache and Pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:Background We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417 , an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881 , in MME (Membrane Metalloendopeptidase). Results We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. Conclusion In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.
-
Screening of genetic variants in ADCYAP1R1, MME and 14q21 in a Swedish cluster headache cohort.
The journal of headache and pain, 2017Co-Authors: Caroline Ran, Carmen Fourier, Julia M. Michalska, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Andrea Carmine BelinAbstract:We have genotyped a Swedish cluster headache case-control population for three genetic variants representing the most significant markers identified in a recently published genome wide association study on cluster headache. The genetic variants were two common polymorphisms; rs12668955 in ADCYAP1R1 (adenylate cyclase activating polypeptide 1 receptor type 1), rs1006417, an intergenic variant on chromosome 14q21 and one rare mutation, rs147564881, in MME (Membrane Metalloendopeptidase). We screened 542 cluster headache patients and 581 controls using TaqMan real-time PCR on a 7500 fast cycler, and pyrosequencing on a PSQ 96 System. Statistical analysis for genotype and allele association showed that neither of the two common variants, rs12668955 and rs1006417 were associated with cluster headache. The MME mutation was investigated with pyrosequencing in patients, of whom all were wild type. In conclusion rs12668955 and rs1006417 do not impact the risk of developing cluster headache in the Swedish population. Also, rs147564881 does not seem to be enriched within the Swedish cluster headache patient group.